Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;9(2):321-331.
doi: 10.1111/jdi.12711. Epub 2017 Aug 17.

Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations

Xueying Gao  1 , Xiaoling Cai  1 , Wenjia Yang  1 , Yifei Chen  1 , Xueyao Han  1 , Linong Ji  1
Affiliations
Review

Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations

Xueying Gao et al. J Diabetes Investig. 2018 Mar.

Abstract

Aims/introduction: To evaluate the efficacy and safety of alpha-glucosidase inhibitors (AGI) in Asian and non-Asian type 2 diabetes patients.

Materials and methods: Studies were identified through a literature search of MEDLINE, EMBASE and other databases until December 2016. All statistical analyses were carried out in Review Manager statistical software by computing the weighted mean difference or odds ratio and 95% confidence interval.

Results: A total of 67 studies were included. AGI vs placebo: compared with the placebo, AGI treatment led to a greater decrease in hemoglobin A1c (HbA1c), fasting plasma glucose and postprandial plasma glucose. No significant difference was observed in HbA1c change, fasting plasma glucose change, postprandial plasma glucose change or incidence of hypoglycemia between Asian and non-Asian patients. AGI vs active controls: in Asian patients, AGI treatment showed a lower reduction in HbA1c compared with dipeptidyl peptidase-4 inhibitors and sulfonylurea. In non-Asian patients, AGI treatment showed a lower reduction in HbA1c compared with thiazolidinedione. No significant difference was observed in HbA1c change and bodyweight change when comparing AGI with other oral hypoglycemic agents between Asian and non-Asian patients.

Conclusions: The effects of AGI treatment on glycemic control and bodyweight reduction were superior to the placebo without an increased incidence of hypoglycemia, but with an increased incidence of gastrointestinal discomforts. The hypoglycemic effects of AGI were comparable between Asian and non-Asian patients.

Keywords: Alpha-glucosidase inhibitors; Asian; Type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The flowchart of studies included in this meta‐analysis. AGI, alpha‐glucosidase inhibitors.
See this image and copyright information in PMC

References

    1. Yang W, Lu J, Weng J, et al Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090–1101. - PubMed
    1. Plus W. Pharmacology of Glucosidase Inhibitors, Vol. 119 Berlin Heidelberg: Springer, 1996; 611–632.
    1. Society CD . Chinese guideline for Type 2 diabetes prevention (2013). Chinese J Diabetes 2014; 22: 2–42.
    1. Chan JC, Chan KW, Ho LL, et al An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet, Asian Acarbose Study Group. Diabetes Care 1998; 21: 1058–1061. - PubMed
    1. Bachmann W, Petzinna D, Raptis SA, et al Long‐term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. Clin Drug Investig 2003; 23: 679–686. - PubMed

MeSH terms

Substances